🇺🇸 FDA
Pipeline program

Mavorixafor

X4P-001-103

Phase 3 small_molecule active

Quick answer

Mavorixafor for WHIM Syndrome is a Phase 3 program (small_molecule) at X4 Pharmaceuticals, Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
X4 Pharmaceuticals, Inc
Indication
WHIM Syndrome
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials